肠道微生物组与接受帕博利珠单抗治疗的宫颈癌和子宫内膜癌患者结局的关联:来自II期PRIMMO试验的探索性研究
II期PRIMMO试验的探索性研究分析了35例复发性/转移性宫颈癌(15例)和子宫内膜癌(20例)患者接受帕博利珠单抗为基础方案治疗前的肠道微生物组。发现疗效好与差的患者在帕博利珠单抗启动前肠道微生物组分类组成上存在 consistent 差异,两个自然发生的微生物组聚类显示超过四倍的死亡风险差异(HR 4.4,95%CI 1.9-10.3,P<0.001)。
要点
- 疗效好者肠道富集Blautia属,疗效差者富集肠杆菌科及其更高分类层级至门水平以及梭菌属及其梭菌科。
- 两个自然发生的肠道微生物组聚类死亡风险差异超过四倍(HR 4.4,95%CI 1.9-10.3,P<0.001)。
- 严重治疗相关不良事件(总体或胃肠道毒性)的发生或抵抗与多个细菌类群的显著富集相关。
核心结论
- 尽管为探索性研究,本研究初步揭示了接受帕博利珠单抗为基础方案治疗的宫颈癌和子宫内膜癌患者肠道微生物组与临床结局之间的复杂相互作用。
研究设计与样本
- II期PRIMMO试验的探索性研究,对35例患者(宫颈癌15例,子宫内膜癌20例)的77份纵向粪便样本进行16S rRNA基因测序。
- 患者为复发性/转移性宫颈癌或子宫内膜癌且至少接受过一线全身治疗。
- 分析包括α多样性(Shannon指数)和β多样性(加权UniFrac)、无偏层次聚类以及线性判别分析效应量。
- 与人口统计学、疾病特征、安全性、疗效和免疫监测数据进行相关性研究。
主要发现
- 疗效好者与疗效差者在帕博利珠单抗启动前的肠道微生物组分类组成上存在 consistent 差异:疗效好者富集Blautia属,疗效差者富集肠杆菌科及其更高分类层级至门水平以及梭菌属及其梭菌科。
- 识别出两个自然发生的肠道微生物组聚类,其细菌组成不同,死亡风险差异超过四倍(HR 4.4,95%CI 1.9-10.3,P<0.001)。
- 这两个聚类与外周免疫监测数据之间呈现有趣但非显著的趋势。
- 严重治疗相关不良事件(总体或胃肠道毒性)的发生或抵抗与多个细菌类群的显著富集相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase II PRIMMO trial investigated a pembrolizumab-based regimen in patients with recurrent and/or metastatic cervical (CC) or endometrial (EC) carcinoma who had at least one prior line of systemic therapy. Here, exploratory studies of the gut microbiome (GM) are presented. METHODS: The microbial composition of 77 longitudinal fecal samples obtained from 35 patients (CC, n = 15; EC, n = 20) was characterized using 16S rRNA gene sequencing. Analyses included assessment of alpha (Shannon index) and beta diversity (weighted UniFrac), unbiased hierarchical clustering, and linear discriminant analysis effect size. Correlative studies with demographics, disease characteristics, safety, efficacy, and immune monitoring data were performed. RESULTS: Significant enrichment in multiple bacterial taxa was associated with the occurrence or resistance to severe treatment-related adverse events (overall or gastrointestinal toxicity specifically). Consistent differences in GM taxonomic composition before pembrolizumab initiation were observed between patients with favorable efficacy (e.g., enriched with Blautia genus) and those with poor efficacy (e.g., enriched with Enterobacteriaceae family and its higher-level taxa up to the phylum level, as well as Clostridium genus and its Clostridiaceae family). Two naturally occurring GM clusters with distinct bacterial compositions were identified. These clusters showed a more than four-fold differential risk for death (hazard ratio, 4.4 [95 % confidence interval, 1.9 to 10.3], P < 0.001) and were associated with interesting (but non-significant) trends in peripheral immune monitoring data. CONCLUSION: Although exploratory, this study offers initial insights into the intricate interplay between the GM and clinical outcomes in patients with CC and EC treated with a pembrolizumab-based regimen. TRIAL REGISTRATION: ClinicalTrials.gov (identifier NCT03192059) and EudraCT Registry (number 2016-001569-97).
引用
- De Jaeghere EA, Hamerlinck H, Tuyaerts S, et al. Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial. Gynecol Oncol. 2024. PMID: 39515198. doi:10.1016/j.ygyno.2024.10.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。